TRCT
BHVN

Tower Research Capital (TRC)’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Tower Research Capital (TRC)’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,928
Closed -$896K – 6983
2022
Q3 		$896K Sell
5,928
-999
-14% -$148K 0.01% 754
2022
Q2 		$1.01M Buy
6,927
+5,211
+304% +$666K 0.02% 681
2022
Q1 		$204K Sell
1,716
-787
-31% -$98.2K ﹤0.01% 1711
2021
Q4 		$344K Buy
2,503
+586
+31% +$74.5K 0.01% 1380
2021
Q3 		$266K Sell
1,917
-3,603
-65% -$450K 0.01% 1535
2021
Q2 		$536K Buy
5,520
+1,278
+30% +$104K 0.01% 1133
2021
Q1 		$290K Sell
4,242
-1,797
-30% -$145K ﹤0.01% 1690
2020
Q4 		$517K Sell
6,039
-6,339
-51% -$537K 0.02% 967
2020
Q3 		$805K Buy
12,378
+8,358
+208% +$548K 0.01% 1191
2020
Q2 		$294K Buy
4,020
+3,327
+480% +$177K 0.01% 1457
2020
Q1 		$24K Buy
693
+689
+17,225% +$31.5K ﹤0.01% 1634
2019
Q4 		$0 Sell
4
-1,678
-100% -$83.1K ﹤0.01% 4940
2019
Q3 		$70K Buy
1,682
+206
+14% +$8.7K ﹤0.01% 1568
2019
Q2 		$65K Buy
+1,476
New +$83.2K ﹤0.01% 1441
2019
Q1 		– Sell
-3,470
Closed -$128K – 4783
2018
Q4 		$128K Sell
3,470
-1,587
-31% -$57.2K 0.01% 857
2018
Q3 		$190K Buy
5,057
+4,337
+602% +$160K 0.01% 1010
2018
Q2 		$28K Sell
720
-368
-34% -$11.7K ﹤0.01% 2229
2018
Q1 		$28K Buy
+1,088
New +$32.5K ﹤0.01% 2009
2017
Q4 		– Sell
-1,010
Closed -$38K – 4538
2017
Q3 		$38K Sell
1,010
-9,991
-91% -$303K ﹤0.01% 2237
2017
Q2 		$275K Buy
+11,001
New +$253K 0.03% 283

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Tower Research Capital (TRC)'s BHVN Position: Q4 2022 in Review

Tower Research Capital (TRC) sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 5,928 shares — an estimated $896K sold.

Tower Research Capital (TRC) first reported a position in BHVN in Q2 2017 and held it in 20 quarters. The position peaked at $1.01M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Tower Research Capital (TRC) reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 5,928 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $896K.
  • Tower Research Capital (TRC) first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 20 quarters.
  • Tower Research Capital (TRC)'s Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.01M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.